Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Savara (NASDAQ:SVRA) released its quarterly earnings data on Tuesday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02), FiscalAI reports.

Savara Stock Performance

NASDAQ SVRA traded down $0.16 during trading hours on Tuesday, hitting $5.57. 1,263,485 shares of the company’s stock traded hands, compared to its average volume of 1,620,952. Savara has a 52 week low of $2.43 and a 52 week high of $7.01. The firm has a market capitalization of $1.14 billion, a P/E ratio of -9.95 and a beta of 0.29. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The business’s fifty day moving average price is $5.63 and its two-hundred day moving average price is $5.50.

Institutional Investors Weigh In On Savara

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. bought a new stake in Savara during the second quarter valued at about $30,000. BNP Paribas Financial Markets lifted its holdings in Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP bought a new position in Savara in the 2nd quarter worth approximately $33,000. Russell Investments Group Ltd. grew its holdings in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new stake in Savara during the 3rd quarter valued at approximately $44,000. Institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on SVRA shares. Oppenheimer initiated coverage on shares of Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.14.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.